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The main causes of morbidity and mortality in diabetes are macro and microvascular com-
plications, including atherosclerosis, nephropathy, and retinopathy. As the definition of
atherosclerosis as a chronic inflammatory disease became widely accepted, it became
important to define the triggers of vascular inflammation. Oxidative and other modifica-
tions of lipids and lipoproteins emerged as major pathogenic factors in atherosclerosis.
Modified forms of LDL (mLDL) are pro-inflammatory by themselves, but, in addition,
mLDLs including oxidized, malondialdehyde (MDA)-modified, and advanced glycation end
(AGE)-product-modified LDL induce autoimmune responses in humans. The autoimmune
response involves T cells in the arterial wall and synthesis of IgG antibodies. The IgG
auto-antibodies that react with mLDLs generate immune complexes (IC) both intra and
extravascularly, and those IC activate the complement system as well as phagocytic cells
via the ligation of Fcγ receptors. In vitro studies proved that the pro-inflammatory activ-
ity of IC containing mLDL (mLDL-IC) is several-fold higher than that of the modified LDL
molecules. Clinical studies support the pathogenic role of mLDL-IC in the development of
macrovascular disease patients with diabetes. In type 1 diabetes, high levels of oxidized
and AGE-LDL in IC were associated with internal carotid intima-media thickening and coro-
nary calcification. In type 2 diabetes, high levels of MDA-LDL in IC predicted the occurrence
of myocardial infarction. There is also evidence that mLDL-IC are involved in the pathogen-
esis of diabetic nephropathy and retinopathy.The pathogenic role of mLDL-IC is not unique
to diabetic patients, because those IC are also detected in non-diabetic individuals. But
mLDL-IC are likely to reach higher concentrations and have a more prominent pathogenic
role in diabetes due to increased antigenic load secondary to high oxidative stress and to
enhanced autoimmune responses in type 1 diabetes.
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INTRODUCTION: LDL MODIFICATION
Oxidative stress is believed to be a critical factor in the initiation
of pathogenic pathways that lead to the development of compli-
cations in diabetes (Giacco and Brownlee, 2010). Hyperglycemia
plays a key role by inducing mitochondrial overproduction of
reactive oxygen species (ROS), which, in turn, will cause oxidative
modification of proteins, enzymes, and other substrates, including
the formation of advanced glycation end (AGE) products (Giacco
and Brownlee, 2010; Miller et al., 2010).
Lipoproteins are among the proteins that are modified as a
consequence of oxidation and glycation. Endothelial cells (EC),
monocytes/macrophages, lymphocytes, and smooth muscle cells
(SMC) are all able to enhance the rate of oxidation of LDL. ROS
and sulfur-centered radicals initiate metal ion-dependent lipid
peroxidation leading to the generation of aldehydes that inter-
act with lysine residues in ApoB-100, resulting in oxidation of
LDL. Alternatively, endothelial injury secondary to oxidative stress
results in increased prostaglandin synthesis and platelet activa-
tion. These processes also cause the formation of aldehydes such
as malondialdehyde (MDA) that interact with the lysine residues
of ApoB-100 (Holvoet, 1999). In vitro, MDA-lysine (as well as
carboxymethyl lysine, carboxyethyl lysine, and other unidentified
modifications) are generated by copper oxidation of LDL. Direct
treatment of LDL with MDA, on the other hand, results in the
formation of highly modified LDL with a 10-fold excess of MDA-
lysine over copper-oxidized LDL (oxLDL) and no other detectable
modifications (Virella et al., 2004).
PATHOGENIC ROLE OF MODIFIED LDL
The pathogenic role of modified lipoproteins in the progression
of atherosclerosis is well established. It has been investigated from
two different angles: the direct pro-atherogenic effect of modified
forms of LDL (mLDL; Lopes-Virella and Virella, 2003; Miller et al.,
2010) and the consequences of the immune response directed
against neoepitopes resulting from lipoprotein modification
(Lopes-Virella and Virella, 2010). Both types of effects have been
extensively characterized in the case of oxLDL. OxLDL is taken
up by macrophages via receptor-mediated pathways other than
the classic LDL receptor (Henriksen et al., 1983; Arai et al., 1989;
Sparrow et al., 1989; Endemann et al., 1993; Penn and Chisolm,
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1994) and it induces accumulation of cholesteryl esters and the
transformation of macrophages into foam cells (Fogelman et al.,
1980; Hoff et al., 1989). It has also been reported that high con-
centrations of oxLDL are cytotoxic and experimental data sug-
gests that oxLDL can injure vascular cells, both endothelial and
SMC (Henriksen et al., 1979; Hessler et al., 1983). Furthermore,
oxLDL induces enhanced synthesis of growth factors, including
PDGF-AA, and PDGF receptor in SMC, as well as of granulocyte-
monocyte colony stimulating factor, macrophage colony stimu-
lating factor, and granulocyte-colony stimulating factor in aortic
EC from humans and rabbits (Rajavashisth et al., 1990). In addi-
tion, oxLDL may affect fibrinolysis, by inhibiting the secretion
of tissue plasminogen activator (tPA) by human EC (Kugiyama
et al., 1993) and stimulating the secretion of plasminogen activa-
tor inhibitor (PAI)-1 (Kugiyama et al., 1993). Thus, oxLDL inhibits
the endothelium-dependent activation of fibrinolysis, possibly
promoting a chronic prothrombotic state.
Oxidized LDL has also been found to have pro-inflammatory
effects relevant to the atherosclerotic process. It has chemotactic
effects on monocytes (Quinn et al., 1987), enhances monocyte
adhesion to EC in culture (Berliner et al., 1990; Kume et al., 1992),
as well as the expression of VCAM-1 and ICAM-1 by human aor-
tic EC induced by TNFα (Kahn et al., 1995) and of ICAM-1 in
resting human endothelial vein cells (Takei et al., 2001). These
pro-inflammatory effects are the result of the activation of a vari-
ety of functional pathways intimately related to innate immunity
processes (Shalhoub et al., 2011). Finally, oxLDL has been shown
to activate a variety of cell types expressing CD36 and other scav-
enger receptors and contribute to the generation of ROS (Li et al.,
2010).
Advanced glycation end-product-modified LDL, as well as
other AGE-modified proteins,are also pro-inflammatory (Vlassara
et al., 2002; Wendt et al., 2002). AGE-modified proteins will impact
EC eliciting increased permeability and pro-coagulant activity
(Vlassara et al., 1994) and inducing the overexpression of VCAM-1
(Schmidt et al., 1995). AGE also contributes to fibroblast prolif-
eration and T cell activation (Vlassara et al., 1994), and activated
T cells in the atheromatous lesions release interferon-γ (De Boer
et al., 1999), which in turn will prime macrophages in the lesion
enhancing the release of pro-inflammatory cytokines and chemo-
tactic factors in response to the recognition of AGE-LDL and other
mLDL by the corresponding receptors. The impact of AGE in
the atherosclerotic process associated with diabetes was confirmed
in streptomycin-induced diabetic ApoE−/− mice. Administration
of soluble forms of AGE receptors (RAGE) resulted in reduc-
tion of vascular permeability and slowed down the progression
of atheromatous lesions (Bucciarelli et al., 2002).
THE IMMUNOGENICITY OF MODIFIED LDL
The pro-inflammatory properties of modified LDL appear to be
considerably enhanced as a consequence of their immunogenic-
ity. The immunogenicity of modified LDL was first reported by
Steinbrecher et al. (1984) based on the immunization of labora-
tory animals with several types of modified LDL. Of all the mLDL,
oxLDL has been studied in greatest detail from the immunolog-
ical point of view. Steinbrecher (1987) as well as Palinski et al.
(1990) characterized its immunogenic epitopes. Furthermore,
human auto-antibodies to oxLDL were the first to be purified and
characterized (Yla-Herttuala et al., 1994; Mironova et al., 1996;
Virella et al., 2000). The cell-mediated immune system is also
activated by antigen-presenting cells presenting modified LDL
oligopeptides together with co-stimulatory signals to Th-1 cells,
resulting in a chronic inflammatory reaction in which interferon-
γ released by Th-1 cells enhances the pro-inflammatory response
of macrophages, including the release of chemokines that attract
more T cells to the area and the process becomes self-perpetuating
(De Boer et al., 1999; Andersson et al., 2010).
CELLULAR RESPONSE TO ANTIGEN-ANTIBODY COMPLEXES
(IMMUNE COMPLEXES) CONTAINING DIFFERENT MODIFIED
FORMS OF LDL
It has been established that atherosclerotic plaque rupture is a crit-
ical event triggering thrombus formation and subsequent acute
coronary events (Libby and Theroux, 2005). Plaques that are
prone to rupture consist of a larger intimal lesion with abundant
macrophages and foam cells and a thinned fibrous cap (Shah,
2002). Necropsy studies have demonstrated that atherosclerosis
in diabetic patients is more diffuse and accelerated than in non-
diabetic patients (Jarrett, 1981). Furthermore, studies have also
shown that atherosclerotic lesions in diabetic patients were more
vulnerable as they had larger intimal lesions and more macrophage
infiltration as compared to those in non-diabetic patients (Moreno
et al., 2000). Analysis of gene expression in atherosclerotic plaques
showed that when compared to stable plaques, vulnerable plaques
have higher expression of matrix metalloproteinases (MMPs) with
collagenase activity, which contribute to the thinning of the fibrous
cap, causing plaque instability and rupture (Galis et al., 1994).
Among the MMPs, MMP-9 has been the object of considerable
interest in recent years, and according to some studies is an inde-
pendent risk factor for atherothrombotic events (Loftus et al.,
2001; Blankenberg et al., 2003). MMP-9 synthesis and release can
be induced through TLR-4 stimulation, usually involving bacterial
endotoxins (Lundberg and Hansson, 2010), but also by minimally
modified LDL (Choi et al., 2009) and likely by other types of
modified LDL.
Besides overexpression of MMPs, vulnerable plaques are char-
acterized by the accumulation of apoptotic macrophages around
the necrotic core (Seimon and Tabas, 2009). A variety of pro-
apoptotic insults has been proposed to play a significant role in
the evolution of atheromas, including oxidative stress, endoplas-
mic reticulum (ER) stress, accumulation of non-esterified (free)
cholesterol, and effects of pro-inflammatory cytokines released
by activated macrophages (Seimon and Tabas, 2009). Most likely
these factors play additive or synergistic effects in the induction of
apoptosis. For example, intracellular accumulation of free choles-
terol is a known inducer of ER stress, but low levels of ER stress
usually protect against apoptosis (Seimon and Tabas, 2009). On
the other hand, accumulation of free cholesterol in macrophages
in combination with signals delivered through scavenger recep-
tors or with interferon-γ, known to be released by activated T
cells in atheromas (De Boer et al., 1999; de Boer et al., 2000),
leads to serine phosphorylation of STAT-1 which is a critical ele-
ment in the induction of apoptosis secondary to ER stress (Lim
et al., 2008). The apoptotic macrophages in atheromas are ingested
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by functional macrophages (efferocytosis). Efferocytosis in early
lesions seems to result in suppression of inflammation, while in
advanced lesions is associated with enhanced inflammation (Sei-
mon and Tabas, 2009). This evolution appears to be the result of
defective efferocytosis in advanced lesions, allowing the apoptotic
cells to undergo necrosis, resulting in the accumulation of cell frag-
ments that promote inflammation and plaque instability (Seimon
and Tabas, 2009).
The activation of functional pathways by oxLDL and immune
complex (IC) containing oxLDL has been studied in detail. oxLDL
has been shown to activate a variety of cell types expressing CD36
and other scavenger receptors and contribute to the generation
of ROS (Li et al., 2010). On macrophages, the interaction of
oxLDL with CD36 (mediated by oxidized phospholipids) results in
activation of the src family members Fyn/Lyn, and of several com-
ponents of the MAP kinase pathway, including MKKK, MKK, FAK,
and mitogen-activated protein kinase (MAPK; c-Jun N-terminal
kinase, c-JNK; Silverstein et al., 2010). The activation of these
kinases and associated proteins such as Vav is associated with
foam cell formation as well as with unregulated actin polymer-
ization and loss of cell polarity causing a migration defect and the
trapping of activated cells in the atheromatous lesions (Silverstein
et al., 2010). In platelets the same signaling events lead to enhanced
platelet reactivity and enhanced formation of thrombi (Silver-
stein, 2009). Recently it has been reported that ligation of CD36
by oxLDL leads to the formation of a TLR-4-TLR-6 heterodimer
that, in turn, will activate MyD88 and NFkB, a critical step in
the induction of the synthesis and release of pro-inflammatory
cytokines (Stewart et al., 2010).
OxLDL-IC have been demonstrated to be more potent acti-
vators of human macrophages than oxLDL (Saad et al., 2006).
The uptake of IC prepared with native or oxLDL by human
macrophages is primarily mediated by Fcγ receptors, primarily
FcγRI (Lopes-Virella et al., 1991, 1997; Oksjoki et al., 2006). It has
been shown that binding of IgG antibody to oxLDL blocks the
interaction of oxLDL with CD36 (Nagarajan, 2007), so CD36 is
not involved in the process. For MDA-LDL-IC and AGE-LDL-IC
FcγRI is also involved, but the possible interaction of these mLDL
with scavenger receptors or receptors for AGE-modified proteins
has not been proven or excluded.
One fundamental property of modified LDL-IC is their ability
to deliver large concentrations of free and esterified cholesterol
to macrophages (Virella et al., 2002). The intracellular accumu-
lation of cholesterol by itself may not induce apoptosis (Seimon
and Tabas, 2009). In fact, both oxLDL-IC and oxLDL (at con-
centrations not exceeding 75µg/mL) have the opposite effect
and prevent macrophage apoptosis (Hundal et al., 2003; Oksjoki
et al., 2006). In vitro data suggests that oxLDL-IC have a pre-
dominantly anti-apoptotic effect, more pronounced than that of
oxLDL (Hammad et al., 2006; Oksjoki et al., 2006) but not unique
to oxLDL-IC, because it has also been reproduced with keyhole
limpet hemocyanin (KLH)-anti-KLH-IC (Oksjoki et al., 2006).
However, there are significant differences between oxLDL-IC and
other IgG-containing IC. Only oxLDL-IC can both engage FcγRI
and deliver cholesterol to the cells and the magnitude of the pro-
inflammatory response induced in human macrophages is greater
with oxLDL-IC than with KLH-IC, for example Saad et al. (2006).
While oxLDL cell signaling is mediated by scavenger receptors,
oxLDL-IC deliver activating signals via Fcγ receptors. The cross-
linking of Fcγ receptors by IC induces phosphorylation of ITAMs
by kinases of the Src family, and consequent activation of Syk
(Crowley et al., 1997; Tohyama and Yamamura, 2009). Activation
of Syk triggers a variety of pathways, including the MAPK signal-
ing cascade, which includes ERK1/2, p38 MAPK, and c-JNK (Luo
et al., 2010), responsible for NFkB activation and the expression
of pro-inflammatory gene products, and the PI3K and AKT path-
way secondary to phospholipase C activation (Oksjoki et al., 2006),
which promotes cell survival by at least four different mechanisms:
(1) phosphorylating the Bad component of the Bad/Bcl-XL com-
plex which results in its dissociation and cell survival, (2) caspase
9 inactivation, (3) regulation of the expression of transcription
factors, and (4) activation of IKK kinases which phosphorylate
IκB and, as a consequence, release the active form of NFkB which
upregulates the expression of genes favoring cell survival (Datta
et al., 1999).
Furthermore, the anti-apoptotic effect of oxLDL-IC seems to
involve additional pathways, including activation of sphingosine
kinase 1, which causes the levels of anti-apoptotic sphingosine-
1-phosphate (S1P) to increase. S1P activates phospholipase C
(PLC) and, through the generation of diacylglycerol, the Ras/ERK,
and phosphokinase C are activated. PLC also activates the P13K-
dependent pathway, which results in Akt activation (Hundal et al.,
2003; Hammad et al., 2006; Chen et al., 2010; Figure 1).
Not surprisingly, the repertoire of oxLDL-IC-induced pro-
survival genes is much wider than that induced by oxLDL alone
(Hammad et al., 2009). Also, oxLDL-IC induce HSP70B expression
in macrophages. This protein binds to the internalized lipid moiety
of oxLDL-IC and prevents its degradation, while at the same time
inducing sphingokinase-1 (Al Gadban et al., 2010; Smith et al.,
2010).
In contrast to oxLDL, there is no published information con-
cerning pathways of cell activation triggered by MDA-LDL or
MDA-LDL-IC. The association of MDA-LDL with acute coronary
syndromes (Holvoet et al., 1998; Holvoet, 1999) and the associa-
tion of high levels of MDA-LDL in the circulating IC isolated from
patients with type 2 diabetes who had acute CVD events, mainly
MI (discussed later in this review), strongly suggest that MDA-
LDL and MDA-LDL-IC have pro-apoptotic activity, although the
precise pathways involved can only be suggested (Figure 1). Pre-
liminary results obtained in our laboratory in experiments expos-
ing human monocyte-derived macrophages to MDA-LDL-IC have
shown increased expression of caspase 3, implying that, in contrast
to oxLDL-IC, MDA-LDL-IC do not activate survival pathways.
This difference between oxLDL and MDA-LDL could be a result of
the large excess of MDA-modified lysine molecules in MDA-LDL
relative to oxLDL (Virella et al., 2005). Also, while copper oxidation
predominantly results in ApoB fragmentation, MDA modification
is associated with ApoB aggregation (Viita et al., 1999). Obviously,
physico-chemical differences in ApoB could determine different
biological properties of the two forms of modified LDL.
Modified LDL isolated from circulating IC reacts with anti-
bodies to oxidized, MDA, and AGE-modified LDL. The content of
these modifications in IC-associated LDL is variable from patient
to patient,but overall it reflects the predominance of a given type of
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FIGURE 1 | Comparison of the pathways responsible for the
anti-apoptotic and pro-apoptotic effects of immune complexes
containing oxidized LDL (oxLDL-IC) and malondialdehyde-modified LDL
(MDA-LDL-IC). OxLDL-IC activate cell proliferation pathways through Syk, a
pathway that leads to activation of Akt and NFkB. The activation of Akt leads
prevents the inactivation of anti-apototic gene products (Bcl-xL in the
diagram). S1P-mediated activation of Akt and proliferation genes has been
suggested by previously published data from our group (Hammad et al.,
2006). This could result from the direct activation of SK1 by Syk, or as a
consequence of the release of growth factors, upon ligation of the
corresponding receptor, which activate S1k via PKC. As for the pro-apoptotic
properties of MDA-LDL-IC, two possible pathways could be involved. One
would result from the simultaneous activation of SK2 (whose phosphorylation
is less stable than that of SK1) and S1PP. This would result in a reduced
generation of S1P, and accumulation of ceramides, which in turn would inhibit
anti-apoptotic genes (Bcl-2 in the diagram) and allow the activation of the
pro-apoptotic intrinsic pathway. An alternative (and not exclusive) pathway to
reach the same effect would involve the degradation of internalized MDA and
release of highly charged phospholipids whose interaction with a CD36-TLR2
complex would activate the generation of ROS and increased cellular stress.
epitope. The enrichment in MDA-modified lysine could explain
the differences in clinical associations that emerged in the data
obtained in the EDIC/DCCT cohort and the VADT patient cohort.
In the EDIC/DCCT cohort, high levels of oxLDL (which in vitro
experiments show that is associated with macrophage survival)
(Oksjoki et al., 2006; Hammad et al., 2009) in isolated IC are strong
predictors of progression of CAD, as assessed by longitudinal mea-
surements of carotid intima-media thickness (IMT; Lopes-Virella
et al., 2011a). In contrast, the levels of MDA-LDL (which in vitro
data show that is associated with macrophage apoptosis) in iso-
lated IC, although associated with CAD progression, are a weaker
predictor, comparable to high levels of LDL-cholesterol (Lopes-
Virella et al., 2011a). This could be a reflection of the fact that at
the time of admission into the DCCT/EDIC cohort the patients
were young and basically CAD-free. Therefore, at that stage, the
pro-apoptotic effect of MDA-LDL-IC would be associated with
effective efferocytosis and the inhibition of the expansion of ath-
erosclerotic lesions (Seimon and Tabas, 2009) However, in older
patients with more advanced lesions, like those included in the
VADT cohort, chronic and extensive ER stress is present lead-
ing to impaired processing of heavily oxidized and aggregated
LDL by macrophages as well as to defective efferocytosis (Hoff
et al., 1993). Defective efferocytosis favors macrophage necrosis
and the release of pro-inflammatory mediators and MMPs leading
to plaque destabilization. Release of cholesterol and oxidized phos-
pholipids also takes place when macrophages undergo necrosis and
the oxidized phospholipids can be transported to the extracellu-
lar compartment and then react with scavenger receptors and/or
TLRs, delivering signals that favor the activation of pro-apoptotic
pathways, increase cellular stress, and block the anti-apoptotic
pathways. Recent data from our laboratory, still unpublished,
supports the pro-apoptotic effect of MDA-LDL-IC in human
macrophages and data obtained in the VADT cohort supports the
role of MDA-LDL-IC in inducing plaque destabilization and acute
CVD events (Lopes-Virella et al., 2012b).
MODIFIED LDL CONCENTRATIONS AS RISK FACTORS FOR
DIABETIC COMPLICATIONS
Our group has studied extensively the pathogenic role of modified
LDL antibodies (Virella et al., 2002, 2008; Saad et al., 2006; Lopes-
Virella et al., 2007, 2011a; Lopes-Virella and Virella, 2010), and
has developed methodology for the measurement of circulating
antibodies to mLDL (Virella et al., 1993) and for the measure-
ment of modified form of LDL and the corresponding antibodies
involved in IC formation through the isolation and fractionation
of circulating IC (Atchley et al., 2002; Virella et al., 2004, 2005,
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2008). Several groups reported studies concerning the possible
association between modified LDL (particularly oxLDL) or the
corresponding antibodies with cardiovascular disease with con-
flicting results (Virella and Lopes-Virella, 2003; Lopes-Virella and
Virella, 2010). The proposed assays for modified LDL are mostly
enzymoimmunoassays and are affected by fact that 95% of circu-
lating modified LDL exists as part of IC (Virella et al., 2004), a
well-known cause of error in both antigen and antibody assays.
The interference of IC was never clearly addressed in the assays
used by different groups, and there has been no effort to develop
a standard assay that could accurately measure circulating forms
of modified LDL. Orekhov et al. (1991, 1995) first called attention
to the use of circulating IC containing LDL as markers indicative
of the severity of the atherosclerotic process. Their methodology
consisted of precipitating IC from serum samples and measuring
the cholesterol content in the precipitates as a surrogate marker for
LDL. We used a similar approach in our initial attempts to mea-
sure LDL-IC levels (Lopes-Virella et al., 2007), but we decided that
a direct measurement of modified LDL in precipitated IC would
be more specific and informative. Our current approach, as pre-
viously noted, involves isolation and fractionation of circulating
IC and allows to measure the levels of different forms of modified
LDL involved in IC formation without interference of the high
affinity IgG auto-antibodies (Virella et al., 2005). The composi-
tion of those IC should reflect that of the complexes deposited
in the arterial wall, given that both LDL and IgG antibodies can
diffuse across the endothelial barrier (Langer et al., 1972; Virella,
2007).
Data generated in clinical studies carried out on a type 1 dia-
betes cohort (the DCCT/EDIC cohort) have shown that high levels
of oxLDL and AGE-LDL in circulating IC are associated with
increased odds to develop diabetic nephropathy (Lopes-Virella
et al., 2012a) and progression of retinopathy (Lopes-Virella et al.,
2012c). Also in nephropathy, predominance of IgG antibodies
(particularly those with higher avidity) over IgM antibodies in
oxLDL-IC was associated with parameters indicative of deterio-
rating renal function in same cohort (Atchley et al., 2002; Virella
et al., 2008). Using coronary artery calcification (CAC) indices
and carotid IMT as end-points indicative of cardiovascular dis-
ease progression we also found that increased levels of oxLDL and
of AGE-LDL in circulating IC are associated in the DCCT/EDIC
cohort with the development of coronary calcification and with
increased levels and progression of carotid IMT. The levels of
MDA-LDL in isolated IC show a significant but weaker correla-
tion with increased carotid IMT (Lopes-Virella et al., 2011a,b). In
contrast, in patients with type 2 diabetes (VADT cohort), the lev-
els of oxLDL and AGE-LDL in circulating IC are not significantly
associated with the occurrence of acute events but high concen-
trations of MDA-LDL in IC are strong predictors of acute events,
especially myocardial infarction (Lopes-Virella et al., 2012b). It
must be noted that Holvoet et al. (1995, 1998) reported in two
separate studies a link between high levels of oxLDL and estab-
lished CAD and between elevated plasma MDA-LDL levels and
plaque instability. As previously discussed, the association of cir-
culating MDA-LDL and IC-associated MDA-LDL specifically with
plaque instability/acute CV events raises interesting questions such
as whether differences in the predominant species of modified
LDL involved in IC formation may induce distinct cell signaling
patterns and, in the case of IC carrying predominantly MDA-
LDL, lead to plaque instability by inducing macrophage apoptosis
and/or increased synthesis of MMPs, such as MMP-9 (Koenig and
Khuseyinova, 2007), known to break down collagen and thus con-
tribute to plaque thinning and rupture. This is very novel concept,
proposing that the effects of the interaction of IC with phagocytic
and antigen-presenting cells depend not only of the engagement
of Fcγ receptors but also of the physico-chemical characteristics
of the antigen.
One significant question that has not yet been directly answered
is whether the formation and pathogenic role of IC contain-
ing modified LDL is unique to patients with diabetes. The fact
that antibodies to modified LDL have also been detected and
isolated from non-diabetic patients with coronary heart disease
and healthy volunteers (Virella et al., 1993, 2002) and that IC
complexes prepared with human oxLDL and human oxLDL anti-
bodies isolated from patients with diabetes and healthy volunteers
have similar pro-atherogenic and pro-inflammatory properties
(Virella et al., 2002) argues in favor of a general role of LDL-
IC in the pathogenesis of atherosclerosis. On the other hand,
IC isolated from patients with type 2 diabetes and macrovascu-
lar disease are enriched in cholesterol and apolipoprotein B and
induce significantly higher accumulation of cholesterol than IC
isolated from non-diabetic patients with coronary artery disease
or from healthy volunteers (Mironova et al., 2000). This could
reflect an enhanced generation of modified LDL in diabetes, due
to the increased oxidative stress, and to a lower content of antiox-
idants in the LDL isolated from diabetic patients (Mironova et al.,
2000). An increased antigenic load would lead to a more vigorous
immune response and to higher levels of IC containing modi-
fied LDL, thus resulting in a more prominent pathogenic role in
diabetes.
MODIFIED FORMS OF LDL AS BIOMARKERS OF PLAQUE
INSTABILITY
There is considerable interest in identifying biomarkers indica-
tive of plaque instability. A variety of proteins and enzymes have
been proposed as candidates, as reviewed recently by Koenig
and Khuseyinova (2007). Besides MMPs, C-reactive proteins
(CRP), cytokines (IL-6, IL-18), enzymes [glutathione peroxi-
dase, lipoprotein-associated phospholipase A2 (Lp-PLA2), type II
secretory phospholipase A2, myeloperoxidase, MMPs, particularly
MMP-9, and pregnancy-associated plasma protein A], chemotac-
tic proteins (monocyte chemotactic protein-1), placental growth
factor, soluble CD40 ligand, soluble Fas ligand, and oxLDL have
been proposed as indicators of plaque instability (Holvoet et al.,
1995, 1998; Holvoet, 1999; Loftus et al., 2001; Pelisek et al., 2009;
Colley et al., 2011). CRP has been extensively studied and sev-
eral studies support the correlation between CRP levels and risk
to suffer an acute cardiovascular event, but its predictive power
beyond the traditional risk factors remains unproven (Koenig and
Khuseyinova, 2007). Similar uncertainties, often compounded by
lack of precise measuring methods, apply to most other proposed
indicators of plaque instability (Koenig and Khuseyinova, 2007).
Of these markers, MDA-LDL and MDA-LDL-IC, oxLDL-IC,
Lp-PLA2, TIMPs, and MMPs appear the most likely to have clinical
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relevance, given the results obtained in preliminary clinical studies
and/or their biological properties that are directly related plaque
instability (Holvoet et al., 1995, 1998; Holvoet, 1999; Loftus et al.,
2001; Koenig and Khuseyinova, 2007; Lopes-Virella et al., 2007,
2011a,b, 2012b; Pelisek et al., 2009; Colley et al., 2011). However,
most studies have been carried out in small patient populations,
and the results are not consistent. Our studies in the DCCT/EDIC
and VADT cohorts of patients with type 1 and type 2 diabetes are
exceptions to this rule, and have demonstrated significant associ-
ations not only with cardiovascular disease (Lopes-Virella et al.,
2007, 2011a,b), but also with nephropathy (Lopes-Virella et al.,
2012a) and retinopathy (Lopes-Virella et al., 2012c). This high
predictive power of the measurement of mLDL in IC reflects the
fact that our assay allows the accurate measurement of the lev-
els of different modifications of the LDL molecules contained
in IC (Virella and Lopes-Virella, 2003; Virella et al., 2005). This
is extremely significant, because, as previously mentioned, 95%
or more of the modified LDL in circulation is associated with
the corresponding antibodies forming IC (Virella et al., 2004),
and because IC containing modified LDL are considerably more
pathogenic than modified LDL by itself as consequence of their
ability to engage Fcγ receptors and activate phagocytic cells to a
much greater extent (Virella et al., 2002; Saad et al., 2006). Ongo-
ing studies will further define the predictive value of the analysis
of the content of mLDL in circulating IC, which at the present
time appears to have the potential to become the best predictor
of progression and complications of cardiovascular disease in dia-
betic patients. Also in the planning stages are studies aimed at
proving that the same predictive value will extend to non-diabetic
populations.
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